Anyone on a CDK 4/6 (such as palbociclib or ribociclib) inhibitor with fulvestrant?

Hello,

 

I work in the Policy and Campaigns Team at Breast Cancer Care and I wanted to ask if anyone is, or has been, on a CDK 4/6 inhibitor (such as palbociclib or ribociclib) with fulvestrant for treating HR postive, HER2 negative locally advanced or secondary breast cancer? 

 

We’re feeding back to the Scottish Medicines Consortium (SMC) at a Patient and Clinician Engagement (PACE) group and looking for patient input so we’d be interested to hear from you. You can email me at olivia.lam@breastcancercare.org.uk or reply to this post.

 

Thank you!

Olivia